What is Ixazomib citrate?
Listen to pronunciation. (ik-SA-zoh-mib SIH-trayt) A drug used with lenalidomide and dexamethasone to treat multiple myeloma. It is used in patients who received at least one other anticancer treatment.
What type of drug is Ixazomib?
Ixazomib is in a class of medications called proteasome inhibitors. It works by helping to kill cancer cells.
Is Ixazomib a proteasome inhibitor?
Ixazomib, as a proteasome inhibitor, inhibits the chymotrypsin-like activity of the β5 subunit of the 20S proteasome. Based on the TOURMALINE-MM1 study, ixazomib was proved by the FDA as the orphan drug in November 2015.
Is Ixazomib chemotherapy?
Ixazomib is used to treat multiple myeloma (bone marrow cancer), in combination chemotherapy with lenalidomide and dexamethasone. This combination is usually given after treatment with at least one other cancer medicine has failed.
How does Marizomib work?
Marizomib is a small molecule that inhibits a large protein complex called the proteasome whose role is to degrade abnormally folded or damaged proteins. The proteasome also regulates several proteins involved in cell growth, cell division, and cell survival.
How is Cybord administered?
How Is This Treatment Given? Bortezomib is given under your skin using a small needle (subcutaneous or Subcut) or through an IV (injected into a vein). This is done at the hospital. You will have a blood test before each treatment cycle to make sure it is safe for you to get treatment.
How do you pronounce Ixazomib?
Pronunciation : ik-SA-zoh-mib Latest prescription information about Ixazomib.
Is Ixazomib FDA approved?
In November 2015, the US FDA approved ixazomib for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
What is the citrate salt form of ixazomib?
Ixazomib Citrate is the citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity.
How does ixazomib work as a proteasome inhibitor?
Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Ixazomib (MLN2238) induces autophagy.
What is the bioavailability of ixazomib in urine?
The mechanism of action of ixazomib is as a Proteasome Inhibitor. After oral administration, the time to reach maximum concentration in plasma was 1 hour. The mean absolute oral bioavailability is 58%. 62% in urine and 22% in feces.
How is ixazomib used in the treatment of multiple myeloma?
Ixazomib is a small molecule proteasome inhibitor that is used in combination with other antineoplastic agents to treat refractory multiple myeloma. Ixazomib is associated with a low rate of serum enzyme elevations during treatment and to rare instances of clinically apparent, acute liver injury.